CICPD, NCT04381741: CD19 CAR-T Expressing IL7 and CCL19 Combined With PD1 mAb for Relapsed or Refractory Diffuse Large B Cell Lymphoma |
|
|
| Enrolling by invitation | 1 | 24 | RoW | CD19-7×19 CAR-T plus PD1 monoclonal antibody | Second Affiliated Hospital, School of Medicine, Zhejiang University | Diffuse Large B-cell Lymphoma | 09/23 | 09/23 | | |
NCT05659628: CD19 CAR-T Expressing IL-7 and CCL19 Combined With Anti-PD1 in RR-DLBCL |
|
|
| Recruiting | 1 | 24 | RoW | CD19-7×19 CAR-T combined with Tislelizumab | Ningbo No. 1 Hospital, Zhejiang University | Diffuse Large B-cell Lymphoma | 12/24 | 12/26 | | |
